Brief: Tiziana Life Sciences Initiates Program To Develop Intranasal Foralumab In Type 1 Diabetes
18/04/2023 12:11
April 18 (Reuters) - Tiziana Life Sciences Ltd TLSA.O :
* TIZIANA LIFE SCIENCES INITIATES PROGRAM TO DEVELOP
INTRANASAL
FORALUMAB IN TYPE 1 DIABETES
* TIZIANA LIFE SCIENCES - INITIATES PROGRAM TO STUDY
TREATMENT,
DELAY OF TYPE 1 DIABETES USING ITS CONVENIENT SELF-ADMINISTERED
INTRANASAL FORALUMAB
Source text for Eikon: ID:nGNX4MH1VM
Further company coverage: TLSA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tiziana Life Sciences
See all newsBrief: Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis
U.S. STOCKS ON THE MOVE -Viatris, Clear Secure, Bicara
U.S. STOCKS ON THE MOVE-Sharps Technology, Whirlpool, Applovin
U.S. STOCKS ON THE MOVE-Oracle, Vanda, Keysight
Tiziana Life Sciences rises as nasal MS drug shows promise in early study